Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: A case series and review of the literature

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 3, 2014, Pages 237-240

  Kenney, Lisa B ^a   Duffey Lind, Eileen ^a   Ebb, David ^b   Sklar, Charles A ^c   Grier, Holcombe ^a   Diller, Lisa ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cancer survivor; Ifosfamide; infertility; Leydig cell dysfunction; osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FOLLITROPIN; IFOSFAMIDE; LUTEINIZING HORMONE; METHOTREXATE; MIFAMURTIDE; TESTOSTERONE;

ADOLESCENT; ADULT; AZOOSPERMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; CASE REPORT; FEMUR; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE; OLIGOSPERMIA; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SEXUAL FUNCTION; TESTIS ATROPHY; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; TIBIA; UNSPECIFIED SIDE EFFECT; YOUNG ADULT;

46, XY DISORDERS OF SEX DEVELOPMENT; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; COHORT STUDIES; DOXORUBICIN; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUTEINIZING HORMONE; MALE; METHOTREXATE; OSTEOSARCOMA; PROGNOSIS; REVIEW LITERATURE AS TOPIC; SPERMATOGENESIS; TESTIS; TESTOSTERONE; YOUNG ADULT;

EID: 84897496604     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182a27c39     Document Type: Review

References (19)

1. Howell SJ, Shalet SM. Effect of cancer therapy on pituitarytesticular axis. Int J Androl. 2002;25:269-276
2. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered Lancet Oncol. 2005;6:209-218
3. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancers: A report from the Children?s Oncology Group. J Clin Oncol. 2012;30:3408-3416
4. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931
5. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:332-339
6. Meistrich ML, Wilson G, Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992;70:2703-2712
7. Petersen PM, Hansen SW, Giwercman A, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol. 1994;5:355-358
8. Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997;68:1-5
9. Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001;91:613-621
10. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol. 2000;18:4016-4027
11. Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol. 2003;25:292-296
12. Ridola V, Fawaz O, Aubier F, et al. Testicular function of survivors of childhood cancer: A comparative study between ifosfamide-and cyclophosphamide-based regimens. Eur J Cancer. 2009;45:814-818
13. Pectasides D, Pectasides E, Papaxoinis G, et al. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl. 2009;30:280-286
14. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function Pediatr Blood Cancer. 2008;50:347-351
15. Derogatis LR. Derogatis Sexual Functioning Inventory (DSFI). Towson, MD: Clinical Psychometric Research Inc.; 1978
16. Howell SJ, Radford JA, Smets EM, et al. Fatigue, sexual function and mood following treatment for haematological malignancy: The impact of mild Leydig cell dysfunction. Br J Cancer. 2000;82:789-793
17. Howell SJ, Radford JA, Adams JE, et al. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol (Oxf). 2000;52:609-616
18. Greenfield DM, Walters SJ, Coleman RE, et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab. 2007;92:3476-3482
19. Howell SJ, Radford JA, Adams JE, et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf). 2001;55:315-324